Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Base editing against cancer – a gene correction strategy for rhabdoid tumours

Obiettivo

Malignant rhabdoid tumours (MRTs) are among the most aggressive paediatric cancers, with overall survival rates below 30%. The genetic hallmark of MRTs is the biallelic inactivation of SMARCB1 (or, rarely, SMARCA4). This single-driver, loss-of-function alteration disrupts epigenetic regulation, leading to uncontrolled proliferation and impaired differentiation. Unlike many cancers with complex mutational landscapes, MRTs are largely epigenetically driven, which raises the possibility that restoration of SMARCB1 function could reverse malignant phenotypes. Current treatment relies on highly toxic chemotherapy and radiotherapy regimens, which provide limited benefit and cause severe long-term side effects. No targeted therapies exist, underscoring an urgent unmet clinical need.
BEAT-MRT builds on ERC-funded discoveries demonstrating that reintroduction of SMARCB1 halts proliferation and induces differentiation in MRT models, establishing a therapeutic opportunity. We will test whether CRISPR-mediated base editing can be used to correct SMARCB1 mutations in vivo, delivered through engineered virus-like particles or adeno-associated virus vectors. Using luciferase-expressing patient-derived xenograft models, tumour progression will be monitored in real time, and efficacy will be measured as reduced tumour growth and prolonged survival. Molecular analyses will validate SMARCB1 repair and confirm safety.
The main project outcome will be the demonstration that targeted genomic correction of SMARCB1 can control MRT progression in vivo. If successful, this would establish a first-in-class therapeutic approach for a devastating childhood cancer and provide a proof of principle for treating monogenic, epigenetically driven malignancies through functional gene restoration. This PoC will also assess IP, market potential, and business strategy, laying the groundwork for translational development and follow-up funding opportunities.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
Contributo netto dell'UE
€ 150 000,00
Costo totale
Nessun dato

Beneficiari (1)